New Investment in Series A of Ottimo Pharma
LEI: 549300Q7EXQQH6KF7Z84
20 December 2024
RTW Biotech Opportunities Ltd
New Investment in Series A of Ottimo Pharma
RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note a new portfolio company investment in Ottimo Pharma ("Ottimo"), a company pioneering bifunctional medicines to extend the lives of people living with cancer. Ottimo announced the completion of its Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, and a pipeline of follow-on bifunctional assets. The Company participated in the Series A alongside other investment vehicles managed by RTW Investments, LP (the "Investment Manager").
Ottimo Pharma is a private biotechnology company focused on the development of pioneering innovative cancer therapies for solid tumours. Jankistomig is designed as a dual pathway, biparatopic single-agent IgG therapy, targeting both immune checkpoint inhibition and angiogenesis in the treatment of cancer. By advancing this dual-pathway approach, Ottimo aims to offer a wider therapeutic window, improve cancer treatment outcomes and reduce the overall healthcare burden.
Roderick Wong, Managing Partner and CIO at the Investment Manager said, "We are thrilled to support Ottimo Pharma at this pivotal juncture. The innovative approach and promising potential of Jankistomig align with our mission to invest in transformative healthcare solutions. We believe Ottimo's bifunctional antibody approach holds significant promise for addressing unmet needs in oncology, and we look forward to contributing to their continued success."
The full text of the announcement can be accessed at https://ottimopharma.com.
For Further Information
|
RTW Investments, LP |
+44 20 7959 6361 |
|
Woody Stileman, Managing Director, Business Development
Krisha McCune, Director, Investor Relations |
|
|
Cadarn Capital (PR & Communications/Distribution & IR Partner) |
+44 79 8418 4461 |
|
Lucy Clark (PR) |
|
|
David Harris (Distribution) |
+44 73 6888 3211 david@cadarncapital.com |
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield |
+44 20 7260 1000
|
|
Nathan Brown |
|
|
Euan Brown |
|
|
BofA Securities (Joint Corporate Broker) |
+44 20 7628 1000 |
|
Edward Peel |
|
|
Alex Penney |
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
|
+44 14 8170 3100 |
|
Morgan Stanley Fund Services USA LLC |
+1 914 225 8885 |
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund